04-08-2026 23:06 via prnewswire.com

CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second...
Read more »